Newsroom
Category
February 7, 2016
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced interim results from one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). Read the full story at Street Insider.com
February 7, 2016
Can Regulus still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that showed its injection pushed a small group of patients to a 97% sustained virologic response rate after only four weeks of combination therapies using some […]
February 7, 2016
The search for the fountain of youth led to a 2009 discovery that a drug called rapamycin was shown to extend the lifespan of mice. Since that time, studies on the metabolic side effects of rapamycin have made it unclear whether the drug is safe as a long-term treatment. Read the full story at Newsroom […]
February 7, 2016
A drug that has recently drawn scientific attention as a lifespan-booster—at least in mice—seems to be safe in monkeys as well, according to new findings that researchers call “encouraging.” Read the full story at World Science
February 7, 2016
KWEX interviews Anand Karnad, M.D., and Tyler Curiel, M.D., M.P.H., about President Obama’s initiative to put more funding into cancer research. Watch the full story in Spanish at KWEX-TV Univision
February 7, 2016
An influential Texas scientific panel recommended on Thursday that bite-mark analysis not be admissible as evidence in courts, a decision experts said could lead judicial systems in other states to exclude it, too. Read the full story at KFGO Radio